Abstract
OBJECTIVES: Nonpharmacologic delirium management is recommended by current guidelines, but studies on the impact of ICU design are still limited. The study's primary purpose was to determine if a multicomponent change in room design prevents ICU delirium. Second, the influence of lighting conditions on serum melatonin was assessed.
DESIGN: Prospective observational cohort pilot study.
SETTING: The new design concept was established in two two-bed ICU rooms of a university hospital. Besides modifications aimed at stress relief, it includes a new dynamic lighting system.
PATIENTS: Seventy-four adult critically ill patients on mechanical ventilation with an expected ICU length of stay of at least 48 hours, treated in modified or standard rooms.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: The clinical examination included a prospective assessment for depth of sedation, delirium, and pain every 8 hours using validated scores. Blood samples for serum melatonin profiles were collected every 4 hours for a maximum of three 24-hour periods. Seventy-four patients were included in the analysis. Seventy-six percent ( n = 28) of patients in the standard rooms developed delirium compared with 46% of patients ( n = 17) in the modified rooms ( p = 0.017). Patients in standard rooms (vs. modified rooms) had a 2.3-fold higher delirium severity (odds ratio = 2.292; 95% CI, 1.582-3.321; p < 0.0001). Light intensity, calculated using the measure of circadian effective irradiance, significantly influenced the course of serum melatonin ( p < 0.0001). Significant interactions ( p < 0.001) revealed that differences in serum melatonin between patients in standard and modified rooms were not the same over time but varied in specific periods of time.
CONCLUSIONS: Modifications in ICU room design may influence the incidence and severity of delirium. Dedicated light therapy could potentially influence delirium outcomes by modulating circadian melatonin levels.
| Original language | English |
|---|---|
| Journal | Critical Care Medicine |
| Volume | 52 |
| Issue number | 4 |
| Pages (from-to) | e182-e192 |
| ISSN | 0090-3493 |
| DOIs | |
| Publication status | Published - 01.04.2024 |
Funding
| Funders | Funder number |
|---|---|
| Charite - Universitatsmedizin Berlin | |
| Baxter Deutschland GmbH | |
| Drägerwerk AG KGaA | |
| Fresenius Medical Care North America | |
| AbbVie Deutschland GmbH | |
| Einstein Stiftung Berlin | |
| Edwards Lifesciences Germany GmbH | |
| Correvio GmbH | |
| Bundesministerium für Bildung und Forschung | |
| Philips Oral Healthcare | |
| Deutsche Forschungsgemeinschaft | |
| European Society of Anaesthesiology and Intensive Care | |
| GRAFT Designhaus GmbH | |
| AGUETT ANT Deutschland GmbH | |
| Masimo Europe Ltd. | |
| Stiftung Charité | |
| Deutsche Gesellschaft für Anästhesiologie | |
| Pfizer Pharma | |
| CytoSorbents Europe | |
| Köhler Chemie GmbH | |
| Sintetica GmbH | |
| German Ministry for Economic Research Funding | KF2882602KJ2 |
| German Ministry for Economics Research Funding | 3 174 589, 3 174 588, US 2017/0224950 A1 |
DFG Research Classification Scheme
- 2.22-12 Cardiology, Angiology